PRL and cancer: Further, we found unique pathways in different cancer types by enriching gene sets that co-occurred in less than four cancer types, i.e., RIG-I-like receptor signaling pathway for colorectal cancer (FDR = 0.02), Notch signaling pathway for AML (FDR = 0.08), TGF-beta signaling pathway for pancreatic cancer (FDR = 0.04), Apelin signaling pathway for liver cancer (FDR = 0.01), prolactin signaling pathway (FDR = 0.03) for prostate cancer.